USP and Public Policy
Left
Refine Your Search
USP appreciates this opportunity to submit comments on FDA’s final rule on the criteria for substances that are generally recognized as safe (GRAS) and on the GRAS notification process.
Learn More
USP appreciates this opportunity to submit comments on the ISO proposal for a new field of technical activity – Medicinal Plants.
Learn More
USP appreciates this opportunity to submit comments on FDA’s revised Draft Guidance on New Dietary Ingredient (NDI) Notifications and Related Issues (Revised Draft Guidance), issued on August 12,…
Learn More
USP welcomes the Food and Drug Administration’s (FDA) issuance of the draft guidance, “Elemental Impurities in Drug Products Guidance for Industry." This draft guidance provides clarity and…
Learn More
USP appreciates the opportunity to comment on the Food and Drug Administration's (FDA) "Request for Quality Metrics Draft Guidance for Industry" (Quality Metrics Draft Guidance). We…
Learn More
USP appreciates the opportunity to comment on the Food and Drug Administration's (FDA) "Nonproprietary Naming of Biological Products" Draft Guidance for Industry" (Draft Guidance).
Learn More
USP appreciates the opportunity to comment on the Food and Drug Administration's (FDA) Proposed Rule, "Designation of Official Names and Proper Names for Certain Biological Products."
Learn More
USP supported FDA regarding the value of public standards as they relate to the integrity of dietary supplements.
Learn More
USP appreciates the Food and Drug Administration’s (FDA) continued work to implement the Food Safety Modernization Act and FDA’s recent Public Meeting to seek comments.
Learn More
USP appreciates the opportunity to provide comments to the Food and Drug Administration (FDA) on the “Compounding Animal Drugs from Bulk Drug Substances Draft Guidance for Industry” (Draft Guidance).
Learn More